136 related articles for article (PubMed ID: 35842528)
1. Primary Tumor Resection is Associated with Improved Disease-Specific Mortality in Patients with Stage IV Small Intestinal Neuroendocrine Tumors (NETs): A Comparison of Upfront Surgical Resection Versus a Watch and Wait Strategy in Two Specialist NET Centers.
Levy S; Arthur JD; Banks M; Kok NFM; Fenwick SW; Diaz-Nieto R; van Leerdam ME; Cuthbertson DJ; Valk GD; Kuhlmann KFD; Tesselaar MET
Ann Surg Oncol; 2022 Nov; 29(12):7822-7832. PubMed ID: 35842528
[TBL] [Abstract][Full Text] [Related]
2. Surgical Management of the Primary Tumor in Stage IV Small Intestinal Neuroendocrine Tumors: To Operate or Not to Operate, That Is the Question.
Dijke K; Kuhlmann KFD; Levy S; Tesselaar MET
Curr Oncol Rep; 2023 Jun; 25(6):679-688. PubMed ID: 37004701
[TBL] [Abstract][Full Text] [Related]
3. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
[TBL] [Abstract][Full Text] [Related]
4. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
5. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.
Daskalakis K; Karakatsanis A; Hessman O; Stuart HC; Welin S; Tiensuu Janson E; Öberg K; Hellman P; Norlén O; Stålberg P
JAMA Oncol; 2018 Feb; 4(2):183-189. PubMed ID: 29049611
[TBL] [Abstract][Full Text] [Related]
6. Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis.
Yan H; Yin L; Han H; Jin Y; Liu Z
J Invest Surg; 2022 Jun; 35(6):1239-1247. PubMed ID: 34991432
[TBL] [Abstract][Full Text] [Related]
7. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.
Lewis A; Raoof M; Ituarte PHG; Williams J; Melstrom L; Li D; Lee B; Singh G
Ann Surg; 2019 Dec; 270(6):1131-1137. PubMed ID: 29746336
[TBL] [Abstract][Full Text] [Related]
8. A "Watch and Wait" Strategy Involving Regular Endoscopic Surveillance Is Safe for Many Patients with Small, Sporadic, Grade 1, Non-Ampullary, Non-Functioning Duodenal Neuroendocrine Tumours.
Exarchou K; Moore AR; Smart HL; Duckworth CA; Howes N; Pritchard DM
Neuroendocrinology; 2021; 111(8):764-774. PubMed ID: 32937631
[TBL] [Abstract][Full Text] [Related]
9. Upfront surgery of small intestinal neuroendocrine tumors. Time to reconsider?
Daskalakis K; Tsolakis AV
World J Gastroenterol; 2018 Aug; 24(29):3201-3203. PubMed ID: 30090001
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.
Cai Y; Liu Z; Jiang L; Ma D; Zhou Z; Ju H; Zhu Y
Front Endocrinol (Lausanne); 2022; 13():871830. PubMed ID: 35937823
[TBL] [Abstract][Full Text] [Related]
11. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
12. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
13. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
[TBL] [Abstract][Full Text] [Related]
15. Primary Tumor Resection Offers Survival Benefit in Patients with Metastatic Midgut Neuroendocrine Tumors.
Polcz M; Schlegel C; Edwards GC; Wang F; Tan M; Kiernan C; Solórzano CC; Idrees K; Parikh A; Bailey CE
Ann Surg Oncol; 2020 Aug; 27(8):2795-2803. PubMed ID: 32430752
[TBL] [Abstract][Full Text] [Related]
16. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with small bowel neuroendocrine neoplasms in Auckland, Aotearoa New Zealand.
McGuinness MJ; Woodhouse B; Harmston C; Parker K; Kramer N; Findlay M; Print C; Merrie A; Lawrence B
ANZ J Surg; 2022 Jul; 92(7-8):1748-1753. PubMed ID: 35762209
[TBL] [Abstract][Full Text] [Related]
19. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
